Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Corvus Pharmaceuticals (CRVS) Research & Development (2022 - 2025)

Corvus Pharmaceuticals (CRVS) has 4 years of Research & Development data on record, last reported at $8.5 million in Q3 2025.

  • For Q3 2025, Research & Development rose 61.89% year-over-year to $8.5 million; the TTM value through Sep 2025 reached $29.0 million, up 66.58%, while the annual FY2023 figure was $16.5 million, 32.46% down from the prior year.
  • Research & Development reached $8.5 million in Q3 2025 per CRVS's latest filing, up from $7.9 million in the prior quarter.
  • Across five years, Research & Development topped out at $10.4 million in Q3 2022 and bottomed at $4.0 million in Q3 2023.
  • Average Research & Development over 4 years is $5.6 million, with a median of $4.8 million recorded in 2022.
  • Peak YoY movement for Research & Development: crashed 61.75% in 2023, then surged 91.37% in 2025.
  • A 4-year view of Research & Development shows it stood at $4.1 million in 2022, then dropped by 1.99% to $4.0 million in 2023, then surged by 30.58% to $5.2 million in 2024, then skyrocketed by 61.89% to $8.5 million in 2025.
  • Per Business Quant database, its latest 3 readings for Research & Development were $8.5 million in Q3 2025, $7.9 million in Q2 2025, and $7.5 million in Q1 2025.